SCHEMBL6309337

SCHEMBL6309337

O=c1nc(NC2CCN(Cc3ccc4c(c3)OCO4)CC2)c2cc(Cl)ccc2n1Cc1cncs1

nearest known ligand 0.73

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 20/20 0.73
KCNH2 Q12809 10/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6315110 0.87 MCHR1 (0.79) MCHR1KCNH2
SCHEMBL6207395 0.87 MCHR1 (0.73) MCHR1KCNH2
SCHEMBL6208310 0.85 MCHR1 (1.00) MCHR1KCNH2
SCHEMBL6208821 0.77 MCHR1 (1.00) MCHR1KCNH2
SCHEMBL6208103 0.75 MCHR1 (0.42) MCHR1KCNH2
SCHEMBL6207386 0.75 MCHR1 (0.81) MCHR1KCNH2
SCHEMBL6208369 0.75 MCHR1 (0.80) MCHR1KCNH2
SCHEMBL5312468 0.74 MCHR1 (0.69) MCHR1KCNH2
SCHEMBL6208889 0.74 MCHR1 (0.83) MCHR1KCNH2
SCHEMBL6206268 0.73 MCHR1 (1.00) MCHR1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6921821-B2 Antagonists of melanin concentrating hormone receptor ABBOTT LABORATORIES (US) 2005-07-26 US claimed
US-20040106645-A1 Antagonists of melanin concentrating hormone receptor MILLENNIUM PHARMACEUTICALS, INC. 2004-06-03 US claimed
US-6921821-B2 Antagonists of melanin concentrating hormone receptor ABBOTT LABORATORIES (US) 2005-07-26 US disclosed
US-20040106645-A1 Antagonists of melanin concentrating hormone receptor MILLENNIUM PHARMACEUTICALS, INC. 2004-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106645-A1 Antagonists of melanin concentrating hormone receptor MCHR1, MCHR2, MC1R MCHR1 1/4885KCNH2 2839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.